U2Bio Co Ltd
221800
Company Profile
Business description
U2Bio Co Ltd provides vitro diagnostic test services. The company generates revenue from vitro diagnostic testing services that include general and molecular diagnostic testing services, and medical IT solution services, which include EMR integration software for health screenings and medical institutions. The company is also pursuing new growth engines in pharmaceutical clinical trials and microbiomes.
Contact
489 Ogeum-ro
4th floor
Songpa-gu
Seoul
KORT: +82 16442068
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
100
Stocks News & Analysis
stocks
10 best global blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalizations look undervalued today.
stocks
3 overvalued ASX shares going into earnings
Prices of these shares exceed our Fair Value Estimate by more than double.
stocks
The long-term case for compounders
Compounders tend to deliver steadier, more durable profit growth across full cycles, making them better suited for long-term investors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,068.80 | 42.20 | -0.46% |
| CAC 40 | 8,181.17 | 54.64 | 0.67% |
| DAX 40 | 24,797.52 | 258.71 | 1.05% |
| Dow JONES (US) | 49,371.39 | 478.92 | 0.98% |
| FTSE 100 | 10,341.56 | 118.02 | 1.15% |
| HKSE | 26,775.57 | 611.54 | -2.23% |
| NASDAQ | 23,653.51 | 191.69 | 0.82% |
| Nikkei 225 | 52,655.18 | 667.67 | -1.25% |
| NZX 50 Index | 13,412.44 | 10.74 | -0.08% |
| S&P 500 | 6,987.10 | 48.07 | 0.69% |
| S&P/ASX 200 | 8,778.60 | 42.50 | -0.48% |
| SSE Composite Index | 4,015.75 | 102.20 | -2.48% |